Third, high metabolic activity might be induced by alternative changes in metabolic drivers, such as mutations in PTEN (observed in approximately 15% of DLBCL) that lead to activation of the P13K/AKT/mTOR pathway [29, 36–38]. This evidence concerns the gene PTEN and diffuse large B-cell lymphoma.